Department of Preclinical Development and Validation

Expert reports: Research and development in immuno-oncology

  • Identification of new diagnostic biomarkers and therapeutic targets for triple-negative breast cancer
  • Development of therapeutic antibodies against validated new target molecules
  • Development of antibody-drug conjugates
  • Development of chimeric antigen receptors
  • Development and validation of special in-vitro models (cell lines, tumoroid models) and in-vivo models (e.g., huCD34+ humanised mouse, PBMC humanised mouse, humanised tumour mouse models, CDX and PDX mouse models)